▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1283 by analyst upside · 2026-08-14
ANTX
AN2 Therapeutics, Inc.
Healthcare · Market Cap $226M · P/E 0x
ANALYST PRICE TARGET
+50.5%
implied upside to consensus target
Current Price $5.98
Consensus Target $9.0
Bull Target $9.0
Bear Target $9.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $1.0
52-Week High $7.19
YTD Return +438.7%
FUNDAMENTALS
Market Cap $226M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.00
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.0
52-Week High $7.19
Current Price $5.98
Bear Target $9.0
Bull Target $9.0
● Now $5.98 ● Target $9.0
TRADING DATA
Avg Volume 291K
YTD Return +438.7%
Analyst Count 2
Consensus Buy
Upside to Target +50.5%
Last Updated 2026-08-14

ANALYST SUMMARY

AN2 Therapeutics, Inc. (ANTX) is currently trading at $5.98 with a Wall Street consensus price target of $9.0, implying potential upside of 50.5% over the next 12 months. 2 analysts currently cover ANTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $9.0, while the most cautious has a target of $9.0.

ANTX operates in the Healthcare sector with a market capitalisation of $226M. The stock is up 438.7% year-to-date and is currently trading near the upper end of its 52-week range of $1.0 – $7.19.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ORMP +42.7%
Oramed Pharmaceuticals Inc.
$182M · P/E 1.1x · Hold
SPOK +27.3%
Spok Holdings, Inc.
$230M · P/E 19.3x · Hold
CGEN +90.9%
Compugen Ltd.
$228M · P/E 6.3x · Buy
INFU +41.2%
InfuSystem Holdings, Inc.
$249M · P/E 31.2x · Buy
PDEX +3.1%
Pro-Dex, Inc.
$217M · P/E 18.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ANTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↑ Upgrade
Market Perform → Outperform 2026-05-14 29% win rate (7 calls)
JMP Securities - Reiterated
Market Outperform → Market Outperform 2025-05-05 Building track record
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-03-26 Building track record
Citizens Capital Markets reit
Market Outperform → Market Outperform 2025-02-25 Building track record
JMP Securities reit
Market Outperform → Market Outperform 2025-02-03 Building track record
JMP Securities reit
Market Outperform → Market Outperform 2024-11-19 Building track record
TD Cowen ↓ Downgrade
Buy → Hold 2024-11-18 Building track record
JMP Securities - Reiterated
Market Outperform → Market Outperform 2024-08-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
8/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →